Notice on Appointment of COO

LUCA Science Inc. (hereinafter referred to as "LUCA") is pleased to announce the appointment of Mr. Stig Ogata as Chief Operating Officer (COO). Mr. Ogata brings with him 30 years of distinguished experience in the pharmaceutical and biotech venture industry mainly at Astellas Pharma.

In his role as the COO, Mr. Ogata will lead the formulation and execution of LUCA's corporate strategy. He will strengthen collaboration among departments, contributing to the overall efficiency and competitiveness of the company.

Mr. Ogata stated, "I am very pleased to be able to participate in the challenge of fulfilling unmet medical needs with the mitochondrial drug platform. It will not be easy, but I look forward to working with our internal and external stakeholders to create new therapies," expressing his commitment to grow alongside LUCA and tackle new challenges.

CEO's Comment:

It is with great pleasure to welcome Mr. Stig Ogata as our new Chief Operating Officer bringing in a wealth of knowledge and leadership to our organization. We are confident that his strategic acumen and deep industry insights will play a pivotal role in steering our organization to new heights.

LUCA will continue to advance its research and development of mitochondrial therapy for further growth and development in collaboration with Mr. Ogata.

[Stig Ogata]

Mr. Ogata’s career includes key roles at Astellas Pharmaceutical Inc., where he served as VP, Head of Corporate Communications and Investor Relations from 2018 to 2020, and later as VP, Head of Audit and Supervisory Committee Office. Prior to that, he played a pivotal role in Astellas Pharma US as Senior Director, leading the establishment of Global Marketing Strategy infrastructure, licensing activities and corporate planning.

Mr. Ogata also served as Chief Operating Officer at Polyphenon Pharma in New York, overseeing the setup of a subsidiary focused on developing a botanical-derived drug for the prevention of prostate cancer.